Cerebrolysin is a drug made from pig brain peptides, registered in more than 50 countries. It is studied in stroke, Alzheimer's disease, and traumatic brain injury as a way to help nerve cells survive and recover.
A mixture of neuropeptide fragments from pig brain (15% peptides, 85% free amino acids). Contains BDNF-, NGF-, and NT-3-like fragments. Registered in 50+ countries.
A neurotrophic drug with clinical data in stroke (2016 meta-analysis: ↓neurological deficit), Alzheimer's (meta-analysis: ↑MMSE +2.4 points), and TBI. 3 level A RCTs. The most extensively studied complex neuropeptide.
Neurotrophic activity: BDNF-, NGF-, CNTF-like fragments → TrkA/TrkB → ↑neuron survival, ↑neurogenesis. ↓β-amyloid toxicity → neuroprotection in Alzheimer's disease. ↑cholinergic transmission. ↑NGF in limbic structures.
Studies used IM or IV injections: 5-10 mL (standard), up to 30-50 mL IV in stroke, for a course of 10-20 days. More than 10 mL per single IM injection was not used.
Level A Human clinical trials. There are randomized controlled trials (RCTs), or the compound has been approved by a regulatory agency. The most reliable level. 3 RCTs. Registered in 50+ countries. Meta-analyses in stroke and Alzheimer's disease.
⚠️ Not suitable for patients with active epilepsy. IV infusion: only in a clinical setting. Allergy is possible (proteins of animal origin).
Research peptides are laboratory reagents (Research Use Only). They are not medicines and are not intended for use in humans or animals.